Skip to search formSkip to main contentSkip to account menu

MGL-3196

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
P1521In a 36-week placebo-controlled phase 2 trial in patients with non-alcoholic steatohepatitis (NASH), treatment with MGL-3196 (resmetirom) significantly reduces atherogenic lipoprotein particles
MGL-3196 is a liver-directed, orally active, highly selective thyroid hormone receptor-β agonist being developed for the… 
2019
2019
SAT-347-MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study
2019
2019
An Investigational Agent for the Treatment of Nonalcoholic Steatohepatitis
Resmetirom (MGL-3196) is an oral, liver-directed, selective thyroid hormone receptor beta agonist. It regulates metabolic… 
2018
2018
MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study
2018
2018
P5387LDL cholesterol, apolipoprotein B, lipoprotein(a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone beta selective agonist, in a 12 week study in HeFH patients
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)